SLex antigen is a complex sugar molecule that is commonly found in numerous types of cancer cells. This molecule has been shown to play a crucial role in the process of tumor metastasis and invasion, as it allows cancer cells to adhere to the endothelial cells lining the walls of blood vessels and spread to other parts of the body. CD BioGlyco is a leading company specializing in the Development of Carbohydrate-Based Vaccines, with a particular focus on Tumor-Associated Carbohydrate Vaccine Development. Our advanced Glyco™ Vaccine Development Platform enables us to provide professional tumor-associated sLex antigen production services to our clients, including but not limited to.
We synthesize the structures of tumor-associated sLex antigens through a series of chemical reactions. We select the appropriate starting compounds followed by chemical modification of the functional groups, and then construct the sugar moieties and specific glycan linkages. Finally, multiple purifications and analyses are performed to ensure that the target molecule meets your requirements.
We synthesize tumor-associated sLex antigens using a specific enzyme-catalyzed reaction. We convert the substrate into the desired sugar structure by selecting the appropriate substrate and enzyme. Compared to chemical synthesis, enzymatic synthesis exhibits higher stereoselectivity and reaction specificity, making it more suitable for your target molecule with high stereoselectivity requirements.
Fig.1 Flowchart of enzymatic synthesis. (CD BioGlyco)
SLex antigen is an important marker on the surface of tumor cells and has an important role in the immunotherapy of cancer. We provide anti-tumor vaccine development services based on sLex antigen as a potential immunotherapy target.
Paper title: One-pot multienzyme synthesis of Lex and sLex antigens.
Abstract: Multi-enzyme synthesis is a method of synthesizing a target molecule using multiple enzyme catalysts in the same system, which is highly efficient and highly stereoselective than traditional chemical synthesis methods. In this publication, the authors designed a "one-pot" reaction system containing multiple enzyme catalysts for the synthesis of Lex and sLex antigens. By optimizing the reaction conditions and controlling the concentration of different enzyme catalysts, the authors successfully achieved a high-yield synthesis process and obtained high-purity products.
Method: The authors applying a one-pot three-enzyme system, selected three enzyme catalysts and added them to the reaction system. These enzyme catalysts can facilitate different synthetic steps, such as the incorporation of some pre-made precursor compounds into the target molecule and the introduction of the desired glycosylated structure into the molecule. Finally, the authors successfully synthesized Lex and sLex antigens in high yields and purity by controlling the reaction conditions such as the concentration of each enzyme catalyst, reaction time, and temperature.
Fig.2 Biosynthetic pathways of Lewis antigens. (Ma, et al., 2021)
Tumor-associated sLex antigen consists of three sugar groups, acetylglucosamine (GlcNAc), galactose (Gal), and N-acetylneuraminic acid (NeuAc), which are composed of the following chemical formula: NeuAcα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-R.
SLex antigen is involved in the metastatic and invasive processes of tumor cells, making it an important target in therapeutic research. Drugs and immunotherapeutic strategies targeting sLex antigen expression have been extensively studied to inhibit the metastatic and invasive ability of tumor cells, thereby improving drug efficacy and patient survival.
At CD BioGlyco, our team of experts has extensive experience in carbohydrate chemistry, immunology, and vaccine development, and we strive to deliver high-quality tumor-associated sLex antigen production that meets our client's specific needs and requirements. For further details, please don't hesitate to contact us!
References
